| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD2-H82E8 | Human | Biotinylated Human CD52 Protein, His,Avitag™ |  |
|
|
| CD2-H525a | Human | Human CD52 Protein, Fc Tag |  |
|
|
| CD2-H82F3 | Human | Biotinylated Human CD52 Protein, Fc,Avitag™ |  |
|
|
Anti-Human CD52 MAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Biotinylated Human CD52, His,Avitag (Cat. No. CD2-H82E8) with an affinity constant of 71.8 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Alemtuzumab | GZ-402673; LDP-03 | Approved | Bayer, Genzyme | LEMTRADA | fda | Chronic lymphocytic leukemia (CLL), Multiple sclerosis (MS) | GENZYME | 2001-05-07 | Chronic lymphocytic leukemia (CLL), Multiple sclerosis (MS) | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Alemtuzumab biosimilar (Hisun Pharm) | IND Filing | Hisun Pharm | Chronic lymphocytic leukemia (CLL) | Details | |
| Campath-1G | Phase Ⅱ | University of Cambridge, GlaxoSmithKline | Graft versus host disease, Transplant rejection | Details | |
| GZ-402668 | GLD-52; GZ-402668 | Phase Ⅰ | Genzyme | Multiple sclerosis (MS) | Details |
| ALLO-647 | ALLO-647 | Phase Ⅱ | Allogene Therapeutics | Non-Hodgkin's lymphoma (NHL) | Details |
| Alemtuzumab biosimilar (Zhangjiang Biotechnology) | Phase Ⅱ | Shanghai Zhangjiang Biotechnology | Chronic lymphocytic leukemia (CLL) | Details | |
| Recombinant anti-CD52 humanized monoclonal antibody (Hisun Pharm) | IND Filing | Hisun Pharm | Chronic lymphocytic leukemia (CLL) | Details |
This web search service is supported by Google Inc.
A-Z